Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?Zacks Investment Research • 07/20/23
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from NovaliqBusiness Wire • 07/18/23
Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023Business Wire • 05/17/23
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?Zacks Investment Research • 05/08/23
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual MeetingBusiness Wire • 05/04/23